

BCI Pharma – CSF1r project

Strategy

Platform of
Selective,
Potent ,
Novel kinase Inh.


Medicinal chemistry

Innovative
Therapy for
Cancer,
Inflammation,
Pain, neuro-
inflammation

Series BCI-386/561

CSF1R, a immunokinase

- Major expression in Macrophages
- Receptor of CSF1 and IL-34



Potential use of CSF1R

- **Cancer** (TAM)
- **Inflammation** (rheumatoid arthritis, Crohn disease, IBD, PsA, OA,...)
- **Neuro-inflammation** (Alzheimer, MS, ALS,.....)
- **Neuropathic Pain**

Technology 2 Partnership

BCI-386/561

BCI – Cancer

Inflammation


Neuroinflammation

Market value : (1)=91bUS\$, (2)=46bUS\$

Born to cure and innovate


BCI cpds and benchmarker

Target based assay screening % Inh phosphorylation at 50nM



BCI compounds shown better potency than PLX3397 and BLZ-945.

% Inh of BCI-386 against 250 kinases at 1 uM





Cell based results (Carna biosciences)

Compounds	IC(50) μ M
PLX-3397	2.2
BLZ-945	0.6
BCI-520	3.5

Cell based assay activity similar to competitors

Modeling studies (ProQsar, valence, SP)

- Interaction map of BLZ-945



Thanks

Dominique.surleraux@bci-pharma.com
<http://www.bci-pharma.com/>